Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XXB 750

Next Previous
X
Search
Drug Profile

XXB 750

Alternative Names: XXB-750

Latest Information Update: 09 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis Pharmaceuticals
  • Class Antihypertensives; Cardiovascular therapies; Heart failure therapies; Monoclonal antibodies
  • Mechanism of Action Atrial natriuretic factor receptor A agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Heart failure; Resistant hypertension

Most Recent Events

  • 27 Aug 2024 Novartis Pharmaceuticals completes a phase II trial in resistant hypertension(In adults, In the elderly) in the US, Australia, Austria, Bulgaria, China, Czechia, France, Germany, Italy, Japan, Netherlands, Poland, Slovakia, Spain, Taiwan and the United Kingdom (NCT05562934)
  • 18 Jan 2024 Novartis Pharmaceuticals completes a phase I trial in Heart failure (In adults , In elderly) in USA and Netherlands(NCT05328752) (EudraCT2021-006683-24)
  • 12 Dec 2023 Phase-II clinical trials in Heart failure (Treatment-experienced) in USA (SC) (NCT06142383)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top